

University of Groningen

Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice

Int CoNNsortium Study Grp; Vorselaars, Wessel M. C. M.; van Beek, Dirk-Jan; Postma, Emily L.; Spiering, Wilko; Rinkes, Inne H. M. Borel; Valk, Gerlof D.; Vriens, Menno R.; Zarnegar, Rasa; Fahey, Thomas J.

Published in:
World Journal of Surgery

DOI:
[10.1007/s00268-019-05074-z](https://doi.org/10.1007/s00268-019-05074-z)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Int CoNNsortium Study Grp, Vorselaars, W. M. C. M., van Beek, D-J., Postma, E. L., Spiering, W., Rinkes, I. H. M. B., ... Vriens, M. R. (2019). Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice. *World Journal of Surgery*, 43(10), 2459-2468. <https://doi.org/10.1007/s00268-019-05074-z>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Validation of the Aldosteronoma Resolution Score Within Current Clinical Practice

Wessel M. C. M. Vorselaars¹ · Dirk-Jan van Beek¹ · Emily L. Postma¹ · Wilko Spiering² ·
Inne H. M. Borel Rinkes¹ · Gerlof D. Valk³ · Menno R. Vriens¹ · International
CONNsorium Study Group

Published online: 3 July 2019
© The Author(s) 2019

Abstract

Introduction Complete resolution of hypertension after adrenalectomy for primary aldosteronism is far from a certainty. This stresses the importance of adequate preoperative patient counseling. The aldosteronoma resolution score (ARS) is a simple and easy to use prediction model only including four variables: ≤ 2 antihypertensive medications, body mass index ≤ 25 kg/m², duration of hypertension ≤ 6 years and female sex. However, because the model was developed and validated within the USA over a decade ago, the applicability in modern practice and outside of the USA is questionable. Therefore, we aimed to validate the ARS in current clinical practice within an international cohort.

Materials and method Patients who underwent unilateral adrenalectomy, between 2010 and 2016, in 16 medical centers from the USA, Europe (EU), Canada (CA) and Australia (AU) were included. Resolution of hypertension was defined as normotension without antihypertensive medications.

Results In total, 514 patients underwent adrenalectomy and 435 (85%) patients were eligible. Resolution of hypertension was achieved in 27% patients within the total cohort and in 22%, 30%, 40% and 38% of patients within USA, EU, CA and AU, respectively ($p = 0.015$). The area under the curve (AUC) for the complete cohort was 0.751. Geographic validation displayed a AUC within the USA, EU, CA and AU of 0.782, 0.681, 0.811 and 0.667, respectively.

Discussion The ARS is an easy to use prediction model with a moderate to good predictive performance within current clinical practice. The model showed the highest predictive performance within North America but potentially has less predictive performance in EU and AU.

Introduction

Primary aldosteronism (PA) is the most common form of secondary hypertension with an estimated prevalence between 5 and 20% depending on the severity of hypertension [1–4]. PA leads to morbidity and mortality through the effects of hypertension and aldosteronism itself on critical organs [5–8]. Therefore, the ultimate goal of treatment is resolution of both. Bilateral adrenal hyperplasia is treated medically while patients with an unilateral aldosterone-producing adenoma (APA) are preferably treated by unilateral adrenalectomy [9–12].

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00268-019-05074-z>) contains supplementary material, which is available to authorized users.

✉ Menno R. Vriens
mvriens@umcutrecht.nl

¹ Department of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, Room G04.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

² Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

³ Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Cure of aldosteronism is reported in the majority of patients after adrenalectomy for APA [13–15]. However, resolution of hypertension, also called cure of hypertension (i.e., a normotensive patient without antihypertensive medications), is far from a certainty. In the past, resolution rates were estimated around 50% [13, 14, 16]. However, recently Williams et al. [15] showed less optimistic results by presenting a 37% resolution rate within a large, international and well-executed study. Moreover, recently our own study group also published on blood pressure-related outcomes after surgery for PA and we presented an even lower resolution rate of 27–30% [17, 18]. This stresses the importance of adequate patient counseling and expectation management before performing an operation. To do this, clinicians need a user-friendly and reliable prediction model.

In 2008, Zarnegar et al. [19] proposed the Aldosteronoma Resolution Score (ARS) as a practical prediction model for resolution of hypertension. The model is very easy to use because it only includes four dichotomous preoperative patient/disease characteristics associated with a high probability of resolution of hypertension: taking ≤ 2 number of antihypertensive medications (AHTN) (2 points), body mass index (BMI) ≤ 25 kg/m² (1 point), duration of hypertension ≤ 6 years (1 point) and female sex (1 point). Based on the combined scores, three likelihood ratios for resolution of hypertension were identified: low (0–1), medium (2–3) and high (4–5) with corresponding likelihoods of resolution of 28%, 46% and 75%, respectively. The area under the curve (AUC) was 0.913 [19].

In the past, validation of the ARS showed contradicting results between studies and was frequently performed within small and single country or single-center study populations. In addition, these studies often included patients treated over several decades due to the low incidence of disease. Furthermore, the ARS was developed over a decade ago and, because of the improvement of diagnostic modalities and guidelines, patient care has made substantial progress over the years. This underscores the need to evaluate the clinical applicability and usefulness of the ARS in the current clinical APA population, especially because the performance of a prediction model may change over time [20–22]. In addition, since the prediction model was developed within the USA, the ARS is likely to have lower predictive value outside of the USA which questions the generalizability of the ARS worldwide. Therefore, we aimed to be the first to validate the ARS in current clinical practice and expand this geographically in a worldwide cohort of patients who had adrenalectomy between 2010 and 2016.

Methods

Patients and data collection

We performed a retrospective cohort study across 16 medical centers in the USA, Europe (EU), Canada (CA) and Australia (AU) (Fig. 1). Derivation of this cohort has been described before [17]. In brief, all patients who underwent unilateral adrenalectomy between 2010 and 2016 for APA were included. Because we aimed to make our study representative for current real-life clinical practice no strict inclusion or exclusion criteria were used regarding screening, case confirmation or subtype testing. Laterality of disease was based on computerized tomography (CT) and/or magnetic resonance imaging (MRI) and/or adrenal venous sampling (AVS). In general, biochemical evidence for PA was based on an elevated aldosterone-to-renin ratio (ARR) indicating PA. Patients with missing preoperative or follow-up data regarding systolic blood pressure (SBP), diastolic blood pressure (DBP) or corresponding number of AHTN were excluded (Fig. 1). Institutional review board approval was obtained in all participating centers.

Definitions and outcomes

Resolution of hypertension was defined as a postoperative normotensive patient (i.e., SBP < 140 mmHg and DBP < 90 mmHg) without antihypertensive medications. Office blood pressure measurements were performed during outpatient visitation. Number of AHTN was defined as the number of different antihypertensive medications used. The defined daily dose (DDD) was calculated with the World Health Organization Anatomical Therapeutic Chemical/DDD Index 2017 (see https://www.whocc.no/atc_ddd_index/). When a medication stop was performed due to laboratory measurements, for example prior to the ARR, the number of AHTN, DDD and corresponding blood pressure before discontinuation were used. Biochemical data were classified as elevated/suppressed when values were above/below the local reference range. Hypokalemia was defined as either a potassium level below the local reference ranges or the use of potassium supplementation. The predictive accuracy of the ARS was reported as the proportion of patients with resolution for every ARS subgroup. Geographic validation was performed after division of the cohort into four geographic regions: USA, EU, CA and AU [20–22]. The goal was to assess resolution of hypertension at follow-up closest to 6 months after adrenalectomy.




Fig. 1 Flowchart of included patients

Statistical analysis

The Chi-Square test and Fisher's exact test were used to analyze group differences for categorical variables. For comparisons of continuous variables between multiple groups, one-way ANOVA was used for normally distributed data and Kruskal–Wallis Test for not normally distributed data. A *p* value of < 0.05 was considered statistically significant. Multiple variables used as predictors in the ARS had missing values. To be able to calculate the ARS in all patients, these variables were imputed using multiple imputation with 20 imputed datasets [23]. The duration of hypertension and BMI was missing in 16% and 8% of patients, respectively. Gender and number of AHTN were known in all patients (Table 1). The primary endpoint of this study (i.e., resolution of hypertension) was known in all patients. Pooled negative predictive values (NPV), positive predictive values (PPV) and AUCs of the ARS for resolution were calculated. Statistical analysis was performed using SPSS version 25.0 (IBM Corp, New York,

USA), and figures were constructed using Graphpad Prism version 7.02 (GraphPad Software Inc, California, USA).

Results


Baseline characteristics are shown in Table 1. Five hundred fourteen patients underwent adrenalectomy and 435 (85%) patients were eligible for analysis. Two hundred forty-eight (57%), 106 (24%), 42 (10%) and 39 (9%) patients were included from USA, EU, CA and AU, respectively. Patients within the USA had a BMI of 30.4 ± 6.7 , which was significantly higher compared to patients from the EU, CA or AU. The other predictors used within the ARS were comparable between the different regions. Furthermore, CT and AVS were performed in 88% and 64% of patients and the use of these modalities was comparable between the regions. A confirmatory test was more frequently performed within EU and AU compared to the USA and CA, 56% and 46% versus 27% and 17%,

Table 1 Baseline characteristics of the complete cohort and stratified by region

Variable	All patients (<i>n</i> = 435) Number (%) or mean ± SD	USA (<i>n</i> = 248) (57%) Number (%) or mean ± SD	Europe (<i>n</i> = 106) (24%) Number (%) or mean ± SD	Canada (<i>n</i> = 42) (10%) Number (%) or mean ± SD	Australia (<i>n</i> = 39) (9%) Number (%) or mean ± SD	Overall <i>p</i> value
Age at surgery (years)	50.7 ± 11.4	50.0 ± 11.6	51.3 ± 10.3	52.5 ± 11.6	51.2 ± 12.4	0.485
Female	186 (43%)	113 (46%)	37 (35%)	19 (45%)	17 (44%)	0.310
Duration of HTN (years) (<i>n</i> = 366)*	9 (0–42)	10 (0–42)	9 (1–33)	7 (1–40)	6 (0–30)	0.220
Body mass index (<i>n</i> = 402)	29.7 ± 6.1	30.4 ± 6.7	28.9 ± 5.1	28.9 ± 4.6	27.5 ± 4.7	0.032
No. AHTN*	3 (0–8)	3 (0–8)	3 (0–7)	3 (1–6)	3 (0–5)	0.598
DDD (<i>n</i> = 405)*	3.7 (0.0–25.3)	3.7 (0.0–25.3)	3.5 (0.0–13.7)	3.9 (1.0–11.0)	2.2 (0.0–8.7)	0.290
Preoperative mean SBP (mmHg)	150 ± 20	151 ± 20	154 ± 19	140 ± 17	149 ± 15	0.002
Preoperative mean DBP (mmHg)	90 ± 13	89 ± 14	92 ± 12	87 ± 9	91 ± 12	0.150
Hypokalemia (<i>n</i> = 429)	317 (74%)	185 (76%)	77 (73%)	29 (69%)	26 (67%)	0.481
Elevated aldosterone level (<i>n</i> = 408)	225 (55%)	124 (52%)	56 (57%)	23 (58%)	22 (69%)	0.316
Suppressed renin level/ activity (<i>n</i> = 370)	245 (66%)	138 (64%)	60 (70%)	31 (86%)	16 (52%)	0.015
ARR indicating PA (<i>n</i> = 361)	341 (95%)	202 (93%)	74 (96%)	36 (100%)	29 (94%)	0.342
Elevated creatinine level (<i>n</i> = 392)	71 (18%)	39 (19%)	19 (18%)	7 (17%)	6 (15%)	0.956
CT performed (<i>n</i> = 432)	378 (88%)	214 (87%)	89 (84%)	37 (88%)	38 (97%)	0.191
AVS performed (<i>n</i> = 434)	278 (64%)	160 (65%)	59 (56%)	28 (67%)	31 (80%)	0.187
MRI performed (<i>n</i> = 434)	72 (17%)	47 (19%)	16 (15%)	4 (10%)	5 (13%)	0.369
Confirmatory test performed	143 (33%)	38 (27%)	80 (56%)	7 (17%)	18 (46%)	<0.001
Surgical procedure						<0.001
EPRA	171 (39%)	79 (32%)	44 (42%)	27 (64%)	21 (54%)	
ELRA	65 (15%)	55 (22%)	8 (8%)	0 (0%)	2 (5%)	
LTA	198 (46%)	113 (46%)	54 (51%)	15 (36%)	16 (41%)	
Open	1 (< 1%)	1 (< 1%)	0 (0%)	0 (0%)	0 (0%)	
Tumor laterality						0.916
Left	260 (60%)	149 (60%)	64 (60%)	23 (55%)	24 (62%)	
Right	175 (40%)	99 (40%)	42 (40%)	19 (45%)	15 (38%)	
Histology (<i>n</i> = 434)						0.058
Adenoma	362 (84%)	209 (85%)	80 (76%)	39 (93%)	34 (87%)	
Hyperplasia	58 (13%)	34 (14%)	20 (19%)	1 (2%)	3 (8%)	
Adenoma/hyperplasia	13 (3%)	4 (2%)	5 (5%)	2 (5%)	2 (5%)	
Follow-up after surgery						<0.001
< 1 month	101 (23%)	95 (38%)	3 (3%)	3 (7%)	0 (0%)	
1– < 3 months	39 (9%)	19 (8%)	11 (10%)	9 (21%)	0 (0%)	
3–9 months	278 (64%)	131 (53%)	81 (76%)	27 (64%)	39 (100%)	
> 9–18 months	17 (4%)	3 (1%)	11 (10%)	3 (7%)	0 (0%)	

*Values not normally distributed given as medians (range)

HTN hypertension, No. AHTN number of antihypertensive medications, SBP systolic blood pressure, DBP diastolic blood pressure, ARR aldosterone-to-renin ratio, PA primary aldosteronism, CT computerized tomography, AVS adrenal venous sampling, MRI magnetic resonance imaging, EPRA endoscopic posterior retroperitoneal adrenalectomy, ELRA endoscopic lateral retroperitoneal adrenalectomy, LTA laparoscopic transabdominal adrenalectomy



respectively. In 64% of patients, follow-up was performed approximately 6 months after surgery (range 3–9 months).

Resolution of hypertension was achieved in 118 (27%) patients within the total cohort and in 54 (22%), 32 (30%), 17 (40%) and 15 (38%) patients within USA, EU, CA and AU, respectively ($p = 0.015$). No differences in resolution rates were found between the centers within each of the four regions (Fig. 2). Patients with and without preoperative AVS achieved resolution of hypertension in 31% and 28%, respectively ($p = 0.524$). No significant differences were seen between patients with and without a confirmatory test ($p = 0.232$). The rates of resolution of hypertension were comparable between the four follow-up periods ($p = 0.442$) (Fig. 3) and between patients with < 1 month and 3–9 months follow-up ($p = 0.400$). Postoperative potassium and aldosterone were measured in 95% and 64% of patients, showing hypokalemia and hyperaldosteronism in 12% and 4%, respectively. Biochemical outcomes stratified per region are presented in supplement 1.

Validation of the ARS in current clinical practice

There were no significant differences in the dichotomous ARS variables between the geographic regions (Table 2). ARS 0, 1, 2, 3, 4 and 5 were observed in 25%, 19%, 20%, 20%, 10% and 6% of patients, respectively (Table 3). These scores were comparable between the four regions ($p = 0.484$). Within the complete cohort, assessment of the proportion of patients with resolution of HTN within each ARS showed a likelihood of 7% in case of ARS 0 and 84%

in case of ARS 5. This corresponded to a NPV of 93% for ARS 0 and a PPV of 84% for ARS 5. The corresponding AUC was 0.751 (95% CI 0.699–0.802). When using the likelihood levels as proposed by Zarnegar et al. [19] ARS 0–1 (low), ARS 2–3 (medium) and ARS 4–5 (high) showed predictive accuracies of 11, 33 and 59%, respectively. The corresponding AUC for this categorical ARS was 0.718 (95% CI 0.664–0.772). Geographic validation showed a NPV of 96% for ARS 0 and a PPV of 79% for ARS 5 with a AUC of 0.782 (95% CI 0.714–0.851) within the USA. In EU, a NPV of 88%, PPV of 75% and AUC of 0.681 (95% CI 0.571–0.792) were observed. Furthermore, a NPV, PPV and AUC of 90%, 100% and 0.811 (95% CI 0.678–0.943) and 60%, 67% and 0.667 (95% CI 0.483–0.851) were found for CA and AU, respectively.

Discussion

This study validated the ARS within a worldwide cohort of patients which is representative for current clinical practice. Validation of the ARS within the complete cohort showed a moderate to good AUC of 0.751. Furthermore, the AUC was 0.782 within current US APA population. Although this prognostic accuracy was lower compared to the original data presented by Zarnegar et al. (AUC 0.913), it could still be considered as moderate to good prognostic performance [19]. Further geographic validation of the ARS displayed a comparable prognostic value within CA (AUC 0.811), but lower prognostic performance within EU

Fig. 3 Rates of resolution of hypertension stratified by duration of follow-up




Table 2 Dichotomous variables used for the ARS stratified by region

Variables	All patients (n = 435)	USA (n = 248) (57%)	Europe (n = 106) (24%)	Canada (n = 42) (10%)	Australia (n = 39) (9%)	Overall p value
	Number (%)	Number (%)	Number (%)	Number (%)	Number (%)	
No. antihypertensive medications ≤ 2	180 (41%)	97 (39%)	49 (46%)	19 (45%)	15 (39%)	0.584
Body mass index ≤ 25 kg/m ² *	98 (23%)	57 (23%)	20 (19%)	11 (26%)	10 (26%)	0.603
Duration of HTN ≤ 6 years*	171 (39%)	91 (37%)	44 (42%)	18 (43%)	18 (46%)	0.499
Female	186 (43%)	113 (46%)	37 (35%)	19 (45%)	17 (44%)	0.310

*Including imputed data

No. number of, HTN hypertension

(AUC 0.681) and AU (AUC 0.667) potentially indicating limited generalizability of the ARS outside the North American population.

The ARS, as introduced in 2008 by Zarnegar et al., is a user-friendly model to predict the likelihood of resolution of hypertension after adrenalectomy for PA [19]. Because the ARS was developed in the USA within a single-center cohort of 100 patients over a decade ago, it is essential to confirm that the model also predicts well in, and thus is generalizable to, APA patients which were treated within other institutions or in different clinical settings and diagnostic protocols [20–22]. This underscores the need for the evaluation of clinical applicability and usefulness of the ARS in the current clinical APA population, especially because the performance of a prediction model may change over time [20–22]. In the past, validation of the prediction model by others showed contradicting results; however, these studies were single center or country and frequently had small sample size [24–26]. Therefore, we chose to perform validation of the ARS within our large and worldwide cohort of patients, which at this time is the best available population to truly evaluate the generalizability in current real-life clinical practice. The results showed a

lower, but still moderate to good, predictive performance of the ARS within the USA (AUC 0.782) compared to the development dataset AUC 0.913 [19]. Usually, this is expected because prediction models are likely to show optimistic results within the development dataset, because all development techniques are prone to produce “overfitted” models, especially when small datasets (with limited numbers of outcomes) are used [20–22]. In line, performance is often poorer in validation studies because of differences in case mix and domains. Because our study contained almost 250 patients from the USA from seven different medical centers, we believe this study shows a good generalizability of the ARS within the USA. Furthermore, results also showed a decent performance within CA (AUC 0.811). Therefore, these results indicate that the ARS could be an easy to use tool for clinicians from North America to use during patient counseling. Nevertheless, results showed a lower predictive performance of the ARS within the EU (AUC 0.681) and AU (AUC 0.667) demonstrating the potential limited transportability of the model to other countries or continents worldwide. Although this is potentially due to differences in case mix and baseline characteristics, our results surprisingly

Table 3 Geographic validation of the aldosteronoma resolution score

Variable	All patients (n = 435)			USA (n = 248) (57%)			Europe (n = 106) (24%)		
	Total	Resolution (n = 118) (27%)	AUC (95% CI)	Total	Resolution (n = 54) (22%)	AUC (95% CI)	Total	Resolution (n = 32) (30%)	AUC (95% CI)
ARS (Cont.)			0.751 (0.699–0.802)			0.782 (0.714–0.851)			0.681 (0.571–0.792)
0	110/435 (25%)	8/110 (7%)		68/258 (27%)	3/68 (4%)		25/106 (24%)	3/25 (12%)	
1	84/435 (19%)	14/84 (17%)		50/258 (20%)	5/50 (10%)		20/106 (19%)	5/20 (25%)	
2	85/435 (20%)	20/85 (24%)		45/258 (19%)	8/45 (18%)		22/106 (21%)	6/22 (27%)	
3	86/435 (20%)	35/86 (41%)		40/258 (16%)	15/40 (38%)		27/106 (25%)	11/27 (41%)	
4	45/435 (10%)	20/45 (44%)		31/258 (12%)	12/31 (39%)		8/106 (7%)	4/8 (50%)	
5	25/435 (6%)	21/25 (84%)		14/258 (5%)	11/14 (79%)		4/106 (4%)	3/4 (75%)	
ARS (Cat.)			0.718 (0.664–0.772)			0.747 (0.674–0.820)			0.649 (0.534–0.764)
0–1	194/435 (44%)	22/194 (11%)		118/258 (47%)	8/118 (7%)		45/106 (43%)	8/45 (18%)	
2–3	171/435 (40%)	55/171 (32%)		85/258 (35%)	24/85 (28%)		49/106 (46%)	17/49 (35%)	
4–5	70/435 (16%)	41/70 (59%)		45/258 (17%)	23/45 (51%)		12/106 (11%)	7/12 (58%)	
Variable	Canada (n = 42) (10%)			Australia (n = 39) (9%)					
	Total	Resolution (n = 17) (40%)	AUC (95% CI)	Total	Resolution (n = 15) (38%)	AUC (95% CI)			
ARS			0.811 (0.678–0.943)			0.667 (0.483–0.851)			
0	10/42 (24%)	1/10 (10%)		8/39 (21%)	2/8 (40%)				
1	5/42 (12%)	0/5 (0%)		10/39 (26%)	3/10 (30%)				
2	10/42 (24%)	5/10 (50%)		7/39 (18%)	2/7 (29%)				
3	12/42 (26%)	6/10 (60%)		7/39 (18%)	3/7 (43%)				
4	1/42 (2%)	1/1 (100%)		4/39 (10%)	3/4 (75%)				
5	4/42 (10%)	4/4 (100%)		3/39 (8%)	2/3 (67%)				
ARS (Cat.)			0.815 (0.686–0.944)			0.653 (0.469–0.836)			
0–1	15/42 (36%)	1/10 (10%)		18/39 (46%)	5/18 (28%)				
2–3	22/42 (52%)	11/17 (65%)		14/39 (36%)	5/14 (36%)				
4–5	5/42 (12%)	5/5 (100%)		7/39 (18%)	5/7 (71%)				

ARS aldosteronoma resolution score, Cont. continuous scale, Cat. categorical, AUC area under the curve, CI confidence interval

showed no clear differences within the four predictors used for the ARS or individual ARSs between the four regions. For instance, although patients from the USA had significant higher BMI compared to the other regions, this did not result in a lower proportion of patients with BMI ≤ 25 kg/m² or more patients with a low ARS (Table 2).

We observed resolution of HTN in 27% of patients which is lower compared to the 42%, 50% and 52% presented in reviews or meta-analyses and the 37% presented within another worldwide study by Williams et al. [13–16]. Most likely, this difference is multifactorial. For instance, these earlier studies included patients treated over several decades ago and therefore the lower rates of resolution could be influenced by the worldwide increase in obesity and background/not PA-related hypertension over the years [27–29]. Furthermore, because we meant our results to be representative for current clinical practice the preoperative workup, including screening, case confirmation and subtype testing, was not as stringent as in other studies. Potentially this led to less favorable outcomes compared to studies only including patients who, for instance, underwent AVS and thus represent more selected study populations. Although our results showed no difference in resolution rates between patients with and without preoperative AVS, we cannot rule out that AVS truly does not improve outcomes because our cohort and study design are subject to confounding by indication. Further blood pressure-related outcomes and the potential benefits of surgery for patients without resolution of hypertension (i.e., reduction in blood pressure and antihypertensive medications) within this cohort were described in detail before [17, 18].

When comparing rates of resolution between the four regions, results showed a significantly lower resolution rate within the USA (22%) compared to EU (30%), CA (40%) and AU (38%). Besides a significantly higher mean BMI within the USA, another potential influence on the lower resolution rate could be the difference in preoperative workup. While CT and AVS were performed just as often within the four regions, a confirmatory test was performed in only 27% of patients within the USA which is lower compared to EU and AU. Furthermore, due to geographic distances within the USA, the period of follow-up was frequently shorter. Although we found no significant differences in resolution rates between patients that did or did not undergo confirmatory testing and between the different follow-up periods, we cannot exclude that this has influenced the outcomes.

Similar to most studies regarding PA, the need for a retrospective design, due to the low prevalence of PA, is one of the weaknesses of our study. This made it impossible to use standardized measurement procedures for clinical outcomes such as blood pressure measurements.

Although the duration of follow-up had no significant influence on resolution of hypertension rates, the short period of follow-up in a substantial number of patients could also be a potential weakness of this study. Also, the limited number of participating medical centers from CA and AU, resulting in relatively wide confidence intervals of the AUC, should be taken into account.

As presented in earlier studies, the distribution of resolution rates might differ across countries or continents, which also was the case in our study [13–16]. In line, predictors for a certain outcome might differ between geographic populations and the effect or magnitude of predictors might change over time. Although dichotomous variables, as used within the ARS, simplify the use of prediction models in daily clinical practice, much information within the data is lost. This was best illustrated by the significant higher mean BMI within the USA, compared to the other three geographic regions, which did not lead to fewer patients with BMI ≤ 25 kg/m² and a lower ARS. Moreover, the cutoffs for dichotomized variables are often driven by the data, hampering the generalizability of prediction models [20–22]. Therefore, in future studies, a prediction model ideally should include continuous instead of dichotomous variables. Moreover, in a world of rising technology and easy access to electronic devices and web-based applications, a prediction model containing continuous variables could be user-friendly as well.

Conclusion

The ARS is a user-friendly prediction model for clinicians during patient counseling with a moderate to good predictive performance within current clinical practice. The model showed the highest predictive performance within North America, but potentially has less predictive performance in EU and AU indicating the potential limited generalizability outside of the North American APA population.

Acknowledgements

International CONNsorium Study Group Rasa Zarnegar MD⁴, Thomas J. Fahey MD⁴, Frederick T. Drake MD^{5,6}, Quan Y. Duh MD⁵, Stephanie D. Talutis MD⁶, David B. McAneny MD⁶, Catherine McManus MD⁷, James A. Lee MD⁷, Scott B. Grant MD⁸, Raymon H. Grogan MD⁹, Minerva A. Romero Aranas MD MPH¹⁰, Nancy D. Perrier MD¹⁰, Benjamin J. Peipert BA¹¹, Michael N. Mongelli BS¹¹, Tanya Castellino MD¹², Elliot J. Mitmaker MD¹⁰, David N. Parente MD¹³, Jesse D. Pasternak MD¹³, Stan B. Sidhu MD¹⁴, Mark Sywak MD¹⁴, Gerardo D'Amato MD¹⁵, Marco Raffaelli MD¹⁵, Valerie Schuermans MD¹⁶, Nicole D. Bouvy MD¹⁶, Hasan H. Eker MD¹⁷, H. Jaap Bonjer MD¹⁷, Els J.M. Anton F. Engelsman MD¹⁷, Nieveen van Dijkum MD¹⁷, Madelon J.H. Metman MD¹⁸, Schelto Kruijff MD¹⁸. Department of Endocrine and Minimally Invasive Surgery, Weill Cornell Medical College, New York, USA. 5. Department of Surgery,

University of California San Francisco, San Francisco, USA. 6. Department of Surgery, Boston University School of Medicine and Department of Graduate Medical Sciences, Boston, USA. 7. Department of Endocrine Surgery, New York-Presbyterian-Columbia University, New York, USA. 8. Department of Surgery, University of Chicago Medical Center, Chicago, USA. 9. Department of Endocrine Surgery, Baylor St. Luke's Medical Center, Houston, USA. 10. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. 11. Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, USA. 12. Steinberg-Bernstein Centre for Minimally Invasive Surgery and Innovation, McGill University Health Centre, Montreal, Canada. 13. Department of Surgery, University Health Network-Toronto General Hospital, Toronto, Canada. 14. Department of Endocrine Surgery, Royal North Shore Hospital, Sydney, Australia. 15. Department of Endocrine and Metabolic Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy. 16. Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands. 17. Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands. 18. Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Conn JW (1955) Presidential address I. Painting background. II. Primary aldosteronism, a new clinical syndrome. *J Lab Clin Med* 45(1):3–17
- Käyser S, Dekkers T, Groenewoud H et al (2016) Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. *J Clin Endocrinol Metab* 101(7):2826–2835
- Douma S, Petidis K, Doumas M et al (2008) Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. *Lancet* 371(9628):1921–1926
- Hannemann A, Wallaschofski H (2012) Prevalence of primary aldosteronism in patient's cohorts and in population-based studies—a review of the current literature. *Horm Metab Res* 44(3):157–162
- Savard S, Amar L, Plouin P et al (2013) Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension* 62(2):331–336
- Mulatero P, Monticone S, Bertello C et al (2013) Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *J Clin Endocrinol Metab* 98(12):4826–4833
- Monticone S, D'Ascenzo F, Moretti C et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 6(1):41–50
- Milliez P, Girerd X, Plouin P et al (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 45(8):1243–1248
- Stowasser M, Gordon R (2016) Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. *Physiol Rev* 96(4):1327–1384
- Al Fehaily M, Duh Q (2004) Clinical manifestation of aldosteronoma. *Surg Clin North Am* 84(3):887–905
- Young W (2003) Minireview: primary aldosteronism—changing concepts in diagnosis and treatment. *Endocrinology* 144(6):2208–2213
- Young W (2007) Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxf)* 66(5):607–618
- Zhou Y, Zhang M, Ke S et al (2017) Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. *BMC Endocr Disord* 17(1):61
- Muth A, Ragnarsson O, Johannsson G et al (2015) Systematic review of surgery and outcomes in patients with primary aldosteronism. *Br J Surg* 102(4):307–317
- Williams T, Lenders JWM, Mulatero P et al (2017) Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes Endocrinol* 5(9):689–699
- Steichen O, Zinzindohoué F, Plouin P et al (2012) Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. *Horm Metab Res* 44(3):221–227
- Vorselaars WMCM, Nell S, Postma EL et al (2019) Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. *JAMA Surg*. <https://doi.org/10.1001/jamasurg.2018.5842> [Epub ahead of print]
- Vorselaars WMCM, Beek DV, Postma EL et al (2019) Clinical outcomes after surgery for primary aldosteronism: evaluation of the PASO-investigators' consensus criteria within a worldwide cohort of patients. *Surgery*. <https://doi.org/10.1016/j.surg.2019.01.031> [Epub ahead of print]
- Zarnegar R, Young W, Lee J et al (2008) The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. *Ann Surg* 247(3):511–518
- Hendriksen JM, Geersing GJ, Moons KG et al (2013) Diagnostic and prognostic prediction models. *J Thromb Haemost* 11:129–141
- Moons KG, Kengne AP, Grobbee DE et al (2012) Risk prediction models: II. External validation, model updating, and impact assessment. *Heart* 98(9):691–698
- Moons KG, Kengne AP, Woodward M et al (2012) Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. *Heart* 98(9):683–690
- van der Heijden GJMG, Donders ART et al (2006) Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. *J Clin Epidemiol* 59(10):1102–1109
- Utsumi T, Kawamura K, Imamoto T et al (2012) High predictive accuracy of aldosteronoma resolution score in Japanese patients with aldosterone-producing adenoma. *Surgery* 151(3):437–443
- Aronova A, Gordon B, Finnerty B et al (2014) Aldosteronoma resolution score predicts long-term resolution of hypertension. *Surgery* 156(6):1387–1392
- Pasquier L, Kirouani M, Fanget F et al (2017) Assessment of the Aldosteronoma resolution score as a predictive resolution score of hypertension after adrenalectomy for aldosteronoma in French patients. *Langenbecks Arch Surg* 402(2):309–314

27. Mills KT, Bundy JD, Kelly TN et al (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation* 134(6):441–450
28. Namekawa T, Utsumi T, Tanaka T et al (2017) Hypertension cure following laparoscopic adrenalectomy for hyperaldosteronism is not universal: trends over two decades. *World J Surg* 41(4):986–990. <https://doi.org/10.1007/s00268-016-3822-5>
29. Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. *JAMA* 303(20):2043–2050

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.